Prenatal Screening Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Prenatal Screening Market Report Overview
The prenatal screening market size was $672.8 million in 2023. The market is expected to grow at a CAGR of more than 1% during 2023-2033. Pre-natal screening describes tests that detect potential problems affecting the viability and development of the fetus. The detection is carried out using both less invasive and more invasive sampling techniques.
Prenatal Screening Market Outlook, 2023-2033 ($ Million)
Buy the Full Report for More Insights into the Prenatal Screening Market Forecast
The Prenatal Screening market research report has been created to understand market behavior, which will help identify quantitative market trends in the In Vitro Diagnostics therapeutic area. The model discusses in detail the impact of COVID-19 on the prenatal screening market for the year 2020 and beyond. The report has extensively covered pipeline products and technologies, which will help in identifying companies with the most robust pipeline. This, in turn, will assist in predictive analysis for designing your in-licensing and out-licensing strategies.
Market Size (2023) | $672.8 million |
CAGR (2023-2033) | >1% |
Forecast Period | 2023-2033 |
Historical Period | 2015-2022 |
Key Segments | · Alpha-Fetoprotein (AFP) Tests
· Free Beta Human Chorionic Gonadotropin (hCG) Tests · Inhibin A Tests · Non-invasive prenatal testing (NIPT) · Pregnancy Associated Plasma Protein A (PAPP-A) Tests · Total Human Chorionic Gonadotropin (hCG) Tests · Unconjugated Estriol (uE3) Tests |
Key Regions | · North America
· Europe · Asia Pacific · South America · Middle East and Africa |
Leading Companies | · Illumina Inc
· BGI Genomics Co Ltd · Yourgene Health Plc · Eurofins Scientific SE · Agilent Technologies Inc |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Prenatal Screening Market Dynamics
In most countries, maternal serum screening and ultrasound remain standard procedures for the screening of pregnant women for chromosome aneuploidies and other birth defects. If these tests are positive, prenatal diagnosis is typically performed via amniocentesis or chorionic villus sampling (CVS). However, both amniocentesis and CVS are invasive techniques that have a risk of fetal death and miscarriage.
On the contrary, there is a recently developed non-invasive prenatal testing (NIPT) method, first released in Hong Kong. NIPT is the subject of more than 10 completed or ongoing clinical trials in China, the UK, and the US. It is considered more sensitive and represents an attractive alternative to both maternal serum screening and invasive follow-up diagnostic techniques.
Growing incidence of Down Syndrome and rising awareness about congenital defects and prenatal screening are driving the prenatal screening market. Sales of prenatal screening devices depend upon disease incidence, live birth rate, and number of pregnant women. Governments in many countries are taking initiatives to implement tests and offer fully funded prenatal screening to all pregnant women. The introduction of Non-Invasive Prenatal Testing (NIPT) has reduced the uptake of serum screening and invasive tests in many countries. GlobalData expects the Prenatal Screening market to be dominated by NIPT within the forecast period.
Prenatal Screening Market Segments
The key segments in the prenatal screening market are Alpha-Fetoprotein (AFP) Tests, Free Beta Human Chorionic Gonadotropin (hCG) Tests, Inhibin A Tests, Non-invasive prenatal testing (NIPT), Pregnancy Associated Plasma Protein A (PAPP-A) Tests, Total Human Chorionic Gonadotropin (hCG) Tests, and Unconjugated Estriol (uE3) Tests. Non-invasive prenatal testing (NIPT) led the prenatal screening market in 2023. This method determines the risk of genetic abnormalities in the fetus by analyzing the cfDNA.
Prenatal Screening Market Analysis by Segments, 2023 (%)
Buy the Full Report for More Segment Insights into the Prenatal Screening Market
Prenatal Screening Market Segmentation by Regions
The key regions in the prenatal screening market are North America, Europe, Asia Pacific, South America, and the Middle East and Africa. In 2023, North America dominated the prenatal screening market. Rates of prenatal screening are relatively high in the US and Canada, with most women being screened using maternal serum markers. While live birth rates are predicted to rise during the forecast period, competitive pricing pressures and the growing adoption of NIPT in the US mean that the North American prenatal screening market is expected to decline.
Prenatal Screening Market Analysis by Regions, 2023 (%)
Buy the Full Report for More Regional Insights into the Prenatal Screening Market
Prenatal Screening Market - Competitive Landscape
A few of the leading companies in the prenatal screening market are:
- Illumina Inc
- BGI Genomics Co Ltd
- Yourgene Health Plc
- Eurofins Scientific SE
- Agilent Technologies Inc
Illumina Inc dominated the market in 2023.
Prenatal Screening Market Analysis by Companies, 2023 (%)
Buy the Full Report for More Company Insights into the Prenatal Screening Market
Segments Covered in the Report
Prenatal Screening Segments Outlook (Value, $ Million, 2015-2033)
- Alpha-Fetoprotein (AFP) Tests
- Free Beta Human Chorionic Gonadotropin (hCG) Tests
- Inhibin A Tests
- Non-invasive prenatal testing (NIPT)
- Pregnancy Associated Plasma Protein A (PAPP-A) Tests
- Total Human Chorionic Gonadotropin (hCG) Tests
- Unconjugated Estriol (uE3) Tests
Prenatal Screening Regional Outlook (Value, $ Million, 2015-2033)
- North America
- Europe
- Asia Pacific
- South America
- Middle East & Africa
Key Inclusions
Currently marketed Prenatal Screening and evolving competitive landscape:
- Insightful review of the key industry trends.
- Annualized total Prenatal Screening market revenue by segment and market outlooks from 2015-2033.
- Market-level data on units, average selling prices, and market values.
Global, Regional, and Country level market specific insights:
- Qualitative market-specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country-specific insights on the market.
- SWOT analysis for the Prenatal Screening market.
- Competitive dynamics insights and trends provided for the Prenatal Screening market.
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
- Country-specific overview of the healthcare system.
- Country-specific reimbursement policies.
- Country-specific medtech regulatory landscape.
Robust methodologies and sources enable the model to provide an extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real-world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: Illumina Inc, BGI Genomics Co Ltd, Yourgene Health Plc, Eurofins Scientific SE, Agilent Technologies Inc, F. Hoffmann-La Roche Ltd, Revvity Inc, Danaher Corp, Abbott Laboratories, Siemens AG, Quidelortho Corp, Thermo Fisher Scientific Inc, Tosoh Corp, and others.
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.
Scope
This report provides:
- Insightful review of the key industry trends.
- Annualized total Prenatal Screening market revenue by segment and market outlooks.
- Market-level data on units, average selling prices, and market values.
- Global, regional, and country-level market-specific insights including qualitative market-specific information with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country-specific insights on the market.
- SWOT analysis for the Prenatal Screening market.
- Competitive dynamics insights and trends provided for the Prenatal Screening market.
- Country-specific overview of the healthcare system.
- Country-specific reimbursement policies.
- Country-specific medtech regulatory landscape.
Reasons to Buy
The model will enable you to:
- Understand the impact of COVID-19 on the Prenatal Screening market.
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the Prenatal Screening market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Prenatal Screening market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Track device sales in the global and country-specific Prenatal Screening market from 2015-2033.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
BGI Genomics Co Ltd
Yourgene Health Plc
Eurofins Scientific SE
Agilent Technologies Inc
F. Hoffmann-La Roche Ltd
Revvity Inc
Danaher Corp
Abbott Laboratories
Siemens AG
Quidelortho Corp
Thermo Fisher Scientific Inc
Tosoh Corp
Myriad Genetics Inc
Others
Frequently asked questions
-
What was the prenatal screening market size in 2023?
The prenatal screening market size was $672.8 million in 2023.
-
What will the prenatal screening market growth rate be during the forecast period?
The prenatal screening market is expected to grow at a CAGR of more than 1% during 2023-2033.
-
Which region dominated the prenatal screening market in 2023?
North America dominated the overall prenatal screening market in 2023.
-
Which segment led the prenatal screening market in 2023?
Non-invasive prenatal testing (NIPT) led the prenatal screening market in 2023.
-
Which are the leading companies in the prenatal screening market?
A few of the leading companies in the prenatal screening market are Illumina Inc, BGI Genomics Co Ltd, Yourgene Health Plc, Eurofins Scientific SE, and Agilent Technologies Inc, among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.